Other research analysts also recently issued reports about the company. Bank of America started coverage on Intellia Therapeutics in a research note on Thursday, June 16th. They issued a “buy” rating and a $70.00 price target for the company. BMO Capital Markets started coverage on Intellia Therapeutics in a research note on Thursday, June 16th. They issued a “market perform” rating and a $54.00 price target for the company. Oppenheimer decreased their price target on Intellia Therapeutics from $160.00 to $130.00 in a research note on Monday, May 9th. Credit Suisse Group assumed coverage on Intellia Therapeutics in a research note on Thursday, April 28th. They set an “outperform” rating and a $100.00 target price for the company. Finally, The Goldman Sachs Group reduced their target price on Intellia Therapeutics from $206.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, May 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $133.78.
Intellia Therapeutics Stock Down 3.2 %
Shares of NASDAQ:NTLA traded down $2.11 during mid-day trading on Friday, reaching $63.32. 2,004,366 shares of the stock were exchanged, compared to its average volume of 1,221,357. The company has a market cap of $4.80 billion, a P/E ratio of -12.59 and a beta of 2.00. Intellia Therapeutics has a one year low of $37.08 and a one year high of $180.59. The stock’s 50 day simple moving average is $55.42 and its 200-day simple moving average is $64.22.
Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.03). The company had revenue of $14.00 million during the quarter, compared to the consensus estimate of $9.50 million. Intellia Therapeutics had a negative net margin of 973.48% and a negative return on equity of 41.00%. The firm’s revenue for the quarter was up 115.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.01) earnings per share. Analysts anticipate that Intellia Therapeutics will post -5.77 EPS for the current fiscal year.
Hedge Funds Weigh In On Intellia Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System raised its holdings in Intellia Therapeutics by 13.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 26,508 shares of the company’s stock valued at $1,372,000 after acquiring an additional 3,160 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Intellia Therapeutics by 170.3% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,480 shares of the company’s stock worth $1,474,000 after buying an additional 17,943 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of Intellia Therapeutics by 7.8% during the 2nd quarter. Los Angeles Capital Management LLC now owns 10,642 shares of the company’s stock worth $551,000 after buying an additional 767 shares in the last quarter. Steward Partners Investment Advisory LLC raised its holdings in shares of Intellia Therapeutics by 10.2% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company’s stock worth $123,000 after buying an additional 220 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its holdings in shares of Intellia Therapeutics by 18.4% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 47,585 shares of the company’s stock worth $2,463,000 after buying an additional 7,405 shares in the last quarter. 85.89% of the stock is owned by institutional investors and hedge funds.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Intellia Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Intellia Therapeutics wasn’t on the list.
While Intellia Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.